Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 274

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 274
---
 Supply Agreement, by and between the Company and CSL, whereby CSL agreed to supply the Company with fibrinogen. On January 14, 2020,      
 the Company received a termination letter, or CSL Termination Letter. In the CSL Termination Letter, CSL demanded a total amount          
 of $820, claiming it was owed the minimum purchase commitment amounts under the Framework Supply Agreement not paid by the Company        
 in 2018 and 2019. In a subsequent correspondence, CSL additionally demanded interest and damages for lost profit, with an aggregate       
 demand amount of $1,476. The Company has disputed CSL’s payment demand and contends that CSL’s demands are baseless under                 
 the Framework Supply Agreement, as the minimum purchase commitment under the Framework Supply Agreement is conditional upon first         
 obtaining approval of the FDA and the European Medicines Evaluation Agency, or EMEA, and other quality and clinical milestones, none      
 of which has occurred. Notwithstanding, CSL claimed to have obtained a valid German court order in its favor and to endeavor to seek      
 for its enforcement in Israel. Company’s position is that CSL’s claim for the payment of the said unshipped minimum purchase              
 commitments lacks any ground under the terms of the Framework Supply Agreement and, moreover, that the Company was never served with      
 German judicial documents (e.g., statement of claim) of CSL with translations in Hebrew, English or Arabic, as required under the         
 applicable German and international rules of proceeding. Consequently, based on advice of a German legal counsel, the Company are         
 in the opinion that the legal proceeding initiated by CSL suffered a fundamental and material procedural error and that no enforceable    
 German judgement could derive thereto. In 2024, the Company has initiated a proceeding in Germany to annul said German court’s            
 purported ruling. A hearing to annul the judgement in Germany is scheduled for April 2025 and a hearing to discuss the enforcement        
 in Israel is scheduled for June 2025. With respect to the hearing to annul the judgment, the judge requested that the parties submit      
 their arguments in writing. The Company submitted its arguments to the German court by way of a brief on April 11, 2025. In May 2025,     
 the German court issued a judgment dismissing the Company’s annulment claim. On July 4, 2025, the Company entered into an agreement       
 with CSL pursuant to which the Company is required to make an immediate payment of $30 and an additional payment of $300, by the